SCHEMBL3577577

SCHEMBL3577577

CCc1ccc(C(=O)OC)cc1Br

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.57
P4HB P07237 1/20 0.53
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA12 O43570 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
XDH P47989 1/20 0.50
CCR6 P51684 1/20 0.49
HKDC1 Q2TB90 1/20 0.49
MAPT P10636 6/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 4/20 0.46
HSD17B10 Q99714 3/20 0.46
KDM4E B2RXH2 3/20 0.46
GLA P06280 1/20 0.46
GAA P10253 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30848162 0.88 P4HB (0.66) NOTUMP4HBCA1CA2CA12
SCHEMBL29975942 0.88 NOTUM (0.55) NOTUMP4HBCA1CA2CA12
SCHEMBL1040017 0.88 NOTUM (0.55) NOTUMP4HBCA1CA2CA12
SCHEMBL18973337 0.88 P4HB (0.66) NOTUMP4HBCA1CA2CA12
SCHEMBL31063216 0.86 NOTUM (0.54) NOTUMP4HBCA1CA2CA12
SCHEMBL17010776 0.86 LOXL2 (0.54) NOTUMP4HBCA1CA2CA12
SCHEMBL17124875 0.86 NOTUM (0.58) NOTUMP4HBCA1CA2CA12
SCHEMBL2358109 0.86 NOTUM (0.53) NOTUMP4HBCA1CA2CA12
SCHEMBL20021938 0.85 NOTUM (0.50) NOTUMP4HBCA1CA2CA12
SCHEMBL17385775 0.85 NPC1 (0.56) NOTUMP4HBCA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116057059-B Deuterated compounds useful as KRAS G12D inhibitors 南京燧坤智能科技有限公司 2024-03-08 CN disclosed
CN-116057059-A Deuterated compounds useful as KRAS G12D inhibitors 南京燧坤智能科技有限公司 2023-05-02 CN disclosed
WO-2022262838-A1 DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS SILEXON AI TECHNOLOGY CO., LTD. (CN) 2022-12-22 WO disclosed
EP-4015514-A1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0]HYDROXAMIC ACIDS AS HDAC INHIBITORS Valo Health, Inc. (US) 2022-06-22 EP disclosed
EP-3292116-B1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0]HYDROXAMIC ACIDS AS HDAC INHIBITORS FORMA THERAPEUTICS INC (US) 2021-10-20 EP disclosed
CN-110078708-B Smo/Bcr-Abl dual-targeting inhibitor and synthetic method and application thereof 东南大学 2020-12-11 CN disclosed
US-9944643-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2018-04-17 US disclosed
WO-2018058148-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE TUFTS UNIVERSITY (US) 2018-03-29 WO disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-20160376272-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 US disclosed
EP-1567511-A1 SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2005-08-31 EP disclosed
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 US disclosed
WO-2004035556-A1 SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-04-29 WO disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US disclosed
US-6245778-B1 1,6-naphthyridine anti-convulsants SMITHKLINE BEECHAM P.L.C. (GB) 2001-06-12 US disclosed
EP-0986559-A1 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-03-22 EP disclosed
EP-0968190-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-01-05 EP disclosed
WO-1998054184-A1 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1998-12-03 WO disclosed
WO-1998041508-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1998-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A NOTUM 2286/4885P4HB 4138/4885CA1 781/4885
US-20160376272-A1 FACTOR XIa INHIBITORS F11, SERPINC1, TFPI NOTUM 757/4885P4HB 1912/4885CA1 2121/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 NOTUM 3017/4885P4HB 4173/4885CA1 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.